Rhoen Klinikum (ETR:RHK) Sets New 12-Month Low at $15.88

Shares of Rhoen Klinikum AG (ETR:RHK) reached a new 52-week low on Friday . The stock traded as low as €15.88 ($18.47) and last traded at €15.88 ($18.47), with a volume of 9895 shares traded. The stock had previously closed at €16.08 ($18.70).

Several research analysts have recently weighed in on RHK shares. Credit Suisse Group set a €16.50 ($19.19) price objective on Rhoen Klinikum and gave the stock a “sell” rating in a research report on Tuesday, November 19th. Berenberg Bank set a €19.75 ($22.97) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Monday, December 2nd. Finally, Independent Research set a €19.80 ($23.02) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. Rhoen Klinikum currently has a consensus rating of “Hold” and a consensus price target of €20.11 ($23.38).

The firm has a market cap of $1.07 billion and a P/E ratio of 26.53. The company has a quick ratio of 1.96, a current ratio of 2.11 and a debt-to-equity ratio of 14.68. The firm has a fifty day moving average of €17.11 and a 200-day moving average of €20.20.

About Rhoen Klinikum (ETR:RHK)

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.

Read More: Initial Coin Offerings entail a high degree of risk

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit